^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted antibody-drug conjugate

    Related drugs:
    Apply
    Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (NCT05208307)
    Phase 2
    Emory University
    Recruiting
    Last update posted :
    08/12/2024
    Initiation :
    07/21/2022
    Primary completion :
    10/21/2025
    Completion :
    10/21/2026
    CD4
    |
    Chr t(4;14) • Chr t(14;16)
    |
    pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)
    Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3) (NCT04162210)
    Phase 3
    GlaxoSmithKline
    Active, not recruiting
    Last update posted :
    06/10/2024
    Initiation :
    04/02/2020
    Primary completion :
    09/12/2022
    Completion :
    06/26/2025
    CD4
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma (NCT05065047)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    01/05/2023
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    CD4
    |
    Blenrep (belantamab mafodotin-blmf)
    A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment (NCT05556798)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    10/04/2022
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    SDC1
    |
    pomalidomide • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)
    A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (COSTA) (NCT05874193)
    Phase 2
    Cristiana Costa Chase, DO
    Not yet recruiting
    Last update posted :
    04/22/2024
    Initiation :
    06/01/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    CD4
    |
    Blenrep (belantamab mafodotin-blmf)
    A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04177823)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    04/19/2024
    Initiation :
    12/09/2019
    Primary completion :
    12/30/2022
    Completion :
    12/30/2022
    CD8
    |
    CD38 positive
    |
    Blenrep (belantamab mafodotin-blmf)
    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE120) (NCT05280275)
    Phase 1/2
    Hellenic Society of Hematology
    Recruiting
    Last update posted :
    12/01/2023
    Initiation :
    04/13/2022
    Primary completion :
    03/15/2026
    Completion :
    03/15/2026
    CD4
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (BelaRd) (NCT04808037)
    Phase 1/2
    Hellenic Society of Hematology
    Active, not recruiting
    Last update posted :
    10/24/2023
    Initiation :
    02/22/2021
    Primary completion :
    09/08/2028
    Completion :
    11/08/2028
    CD4
    |
    lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • dexamethasone injection
    A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma (NCT05573802)
    Phase 1/2
    Hellenic Society of Hematology
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    07/14/2023
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    CD4
    |
    lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)
    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory (NCT05581875)
    Phase 1/2
    Hellenic Society of Hematology
    Not yet recruiting
    Last update posted :
    10/17/2022
    Initiation :
    10/20/2022
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    CD4
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (GEM-BELA-VRd) (NCT04802356)
    Phase 2
    PETHEMA Foundation
    Recruiting
    Last update posted :
    12/06/2021
    Initiation :
    04/07/2021
    Primary completion :
    03/01/2025
    Completion :
    07/01/2025
    CD34
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)